May 02, 2014
1 min read
Save

BLOG: Outlook for Allergan destined to change

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Read more from Darrell E. White

Admit it. You went to ASCRS expecting to join your colleagues in the act of righteous indignation at the CMS data dump of physician Medicare income. I sure did. Boy, did THAT change fast when the news of Valeant and William Ackman teaming up to make a play for Allergan hit the front page of The Wall Street Journal on Tuesday before the meeting! I don’t know about you, but the only time the whole CMS nonsense came up was when another doc made the same observation that I just did.

What do you think? One of our biggest, most important pharmaceutical companies, at least as far as anterior segment surgeons and dry eye docs are concerned, is now “in play.” If history serves, and it always does, Allergan as we know it is going to change. Get the whole story